US20100179128A1 - Xanthine derivatives as selective hm74a agonists - Google Patents

Xanthine derivatives as selective hm74a agonists Download PDF

Info

Publication number
US20100179128A1
US20100179128A1 US12/063,432 US6343206A US2010179128A1 US 20100179128 A1 US20100179128 A1 US 20100179128A1 US 6343206 A US6343206 A US 6343206A US 2010179128 A1 US2010179128 A1 US 2010179128A1
Authority
US
United States
Prior art keywords
chloro
mmol
dihydro
purine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/063,432
Other languages
English (en)
Inventor
Richard Jonathan Daniel Hatley
Jag Paul Heer
John Liddle
Andrew McMurtrie Mason
Ivan Leo Pinto
Shahzad Sharooq Rahman
Ian Edward David Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Assigned to SMITHKLINE BEECHAM CORPORATION reassignment SMITHKLINE BEECHAM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIDDLE, JOHN, HATLEY, RICHARD JOHATHAN DANIEL, PINTO, IVAN LEO, HEER, JAG PAUL, RAHMAN, SHAHZAD SHAROOQ, MASON, ANDREW MCMURTRIE
Assigned to SMITHKLINE BEECHAM CORPORATION reassignment SMITHKLINE BEECHAM CORPORATION CORRECTIVE ASSIGNMENT TO CORRECT THE ADDITIONAL INVENTOR PREVIOUSLY RECORDED ON REEL 020490 FRAME 0326. ASSIGNOR(S) HEREBY CONFIRMS THE IAN EDWARD DAVID SMITH INADVERTANTLY OMITTED FROM PREVIOUS RECORDATION.. Assignors: LIDDLE, JOHN, SMITH, IAN EDWARD DAVID, HATLEY, RICHARD JONATHAN DANIEL, PINTO, IVAN LEO, HEER, JAG PAUL, RAHMAN, SHAHZAD SHAROOQ, MASON, ANDREW MCMURTRIE
Publication of US20100179128A1 publication Critical patent/US20100179128A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Definitions

  • the present invention relates to compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
  • Dyslipidaemia is a general term used to describe individuals with aberrant lipoprotein profiles.
  • the main classes of compounds used for the treatment of patients with dyslipidaemia, and therefore at risk of cardiovascular disease are the statins, fibrates, bile-acid binding resins and nicotinic acid. Nicotinic acid (Niacin, a B vitamin) has been used clinically for over 40 years in patients with various forms of dyslipidaemia.
  • nicotinic acid produces a very desirable alteration in lipoprotein profiles; reducing levels of VLDL and LDL whilst increasing HDL. Nicotinic acid has also been demonstrated to have disease modifying benefits, reducing the progression and increasing the regression of atherosclerotic lesions and reducing the number of cardiovascular events in several trials.
  • HSL hormone-sensitive triglyceride lipase
  • NEFA plasma non-esterified fatty acids
  • CETP cholesterol ester transfer protein
  • nicotinic acid produces a very desirable alteration in lipoprotein profiles; reducing levels of VLDL and LDL whilst increasing HDL. Nicotinic acid has also been demonstrated to have disease modifying benefits, reducing the progression and increasing the regression of atherosclerotic lesions and reducing the number of cardiovascular events in several trials.
  • xanthine derivatives have been synthesised and disclosed in the prior art.
  • EP0389282 discloses xanthine derivatives as potential mediators of cerebrovascular disorders.
  • a range of xanthine derivatives were identified as adenosine receptor antagonists by Jacobson et. al. in J. Med. Chem., 1993, 36, 2639-2644.
  • the present invention provides xanthine derivatives and the use of these derivatives in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
  • diseases of lipid metabolism including dyslipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • the compounds may also be of use in the treatment of inflammatory diseases or conditions, as set out further below.
  • A represents a group selected from
  • X is A1
  • A1 is —O—
  • Y is a ring which is substituted by aryl or heteroaryl, then m is an integer selected from 3, 4 and 5;
  • R 2 is selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, and heteroaryl, each of which may be optionally substituted by one or more of a group independently selected from: C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1-6 haloalkyl, halogen, —CN, —OR 4 , —(CH 2 ) n COR 4 , —C(O)OR 4 , —OCOR 4 , —(CH 2 ) n NR 5 R 6 , —(NH) p CONR 5 R 6 , —OCONR 5 R 7 , and —NR 5 C(O)OR 7 ;
  • the compounds are of use in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
  • diseases of lipid metabolism including dyslipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • the compounds of the present invention may find use as agonists or partial agonists of HM74A.
  • R 1 represents -(alkylene) m -X-(alkylene) n -Y Wherein X represents A, A1, A2 or a direct link;
  • A represents a group selected from
  • cycloalkylene cycloalkenylene, aryl, heteroaryl, heterocyclyl, and —CH 2 —OC(O)—;
  • A1 represents a group selected from:
  • A2 represents:
  • Y represents a group selected from:
  • heteroaryl heterocyclyl, aryl, cycloalkyl, cycloalkenyl, —NH-aryl, —O(CH 2 ) n -aryl, —O-heteroaryl, —OR 5 , —C(O)OR 5 , —C(O)O—C 6 aryl, —OC(O)R 5 , —CH(aryl) 2 , —CH(heteroaryl) 2 , and —C 1-6 haloalkyl;
  • n is an integer selected from 2, 3, 4 and 5;
  • n is an integer selected from 1, 2, 3, 4 and 5;
  • (m+n) is an integer selected from 2 to 10;
  • Y represents a group selected from: —C(O)(CH 2 ) q OR 5 , —C(O)-aryl, —C(O)-heteroaryl, —C(O)-heterocyclyl, heteroaryl, heterocyclyl, Aryl, 3 or 4 ring fused system, —CH(aryl) 2 , —CH(heteroaryl) 2 , —OR 5 , —NR 5 R 6 , —NC(O)OR 8 , —(O) p C(O)NR 5 R 6 , and —NR 5 C(O)R 8 ;
  • Y represents a group selected from: —OR 5 , —NH 2 , and —NC(O)OR 8 ;
  • That ring may be optionally substituted by one or more of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, —NH 2 , —(CH 2 ) q —(O) p —(CH 2 ) p —N(R 5 )C(O)OR 8 , —(CH 2 ) p —N(R 5 )C(O)R 8 , —(CH 2 ) q —(O) p —(CH 2 ) p —C(O)NR 5 R 6 , —(CH 2 ) p —N(R 5 )C(O)N(R 5 )R 6 , —(CH 2 ) p —C(O)N((CH 2 ) m OH)R 5 , —(CH 2 ) p —N(R 5 )—S(O) 2 R 8 , —CH 2
  • X is A1
  • A1 is —O—
  • Y is a ring which is substituted by aryl or heteroaryl, then m is an integer selected from 3, 4 and 5;
  • R 2 is selected from: H; or C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, cycloalkyl, cycloalkenyl heterocyclyl, aryl, and heteroaryl, each of which may be optionally substituted by one or more of: C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1-6 haloalkyl, halogen, —CN, —OR 4 , —(CH 2 ) n COR 4 , —C(O)OR 4 , —OCOR 4 , —(CH 2 ) n NR 5 R 6 , —(NH) p CONR 5 R 6 , —OCONR 5 R 7 , and —NHC(O)OR 7 ; R 3 is selected from: halogen and CN; R 4 is selected from: H, C 1-6 alkyl
  • R 7 is selected from: H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, —(CH 2 ) t cycloalkyl, —(CH 2 ) n cycloalkenyl, —(CH 2 ) t heterocyclyl, —(CH 2 ) t aryl, and —(CH 2 ) t heteroaryl;
  • R 8 is selected from C 1-4 alkyl
  • R 9 is selected from, C 1-6 alkyl C 2-6 alkenyl, C 2-6 alkynyl, —(CH 2 ) n cycloalkyl, —(CH 2 ) n cycloalkenyl, —(CH 2 ) n heterocyclyl, —(CH 2 ) n aryl, and —(CH 2 ) n heteroaryl, CN
  • m represents an integer selected from: 1, 2, 3, 4 and 5
  • n represents an integer selected from: 0, 1, 2, 3, 4 and 5
  • p represents an integer selected from: 0 and 1
  • q represents an integer selected from: 0, 1 and 2
  • t represents an integer selected from: 1 and 2
  • w represents an integer selected from: 2, 3 and 4.
  • X represents A or A1.
  • A is selected from heteroaryl, heterocyclyl, and A1 is selected from CH 2 —O—(CH 2 ) w N(R 5 )C(O)O—, for example CH 2 —O—(CH 2 ) 2 NHC(O)O—, CH 2 —N(R 5 )C(O)O— for example CH 2 —NHC(O)O, CH 2 —N(R 5 )C(O)— for example, CH 2 —NHC(O)—, CH 2 —(O) p —(CH 2 ) q C(O)NR 5 — for example CH 2 C(O)NCH 3 —, CH 2 —N(R 5 )C(O)N(R 5 )— for example CH 2 —NHC(O)NCH 3 —, CH 2 —C(O)N((CH 2 ) m OH)— for example CH 2 —C(O)N((CH)
  • X represents A and A represents a heteroaryl.
  • A represents a heteroaryl comprising a nitrogen heteroatom, for example, triazolyl, furazanyl, oxadiazolyl, tetrazolyl, imidazolyl or pyrazolyl.
  • Y represents an optionally substituted group selected from: aryl, for example phenyl or napthyl, heteroaryl, for example pyridinyl, thiazolyl, thienyl, benzofuranyl or indolyl, and O-aryl, for example O-phenyl.
  • Y is substituted by one or more groups selected from OR 5 for example OH or OCH 3 , halogen, for example F or Cl, aryl, for example phenyl, C 1-6 haloalkyl for example CF 3 or CH 2 CF 3 , OCF 3 , (R 8 ) P CN for example CN, (CH 2 ) p —N(R 5 )—S(O) 2 R 8 , for example NHSO 2 CH 3 and SO 2 R 9 , for example SO 2 CH 3 .
  • OR 5 for example OH or OCH 3
  • halogen for example F or Cl
  • aryl for example phenyl
  • C 1-6 haloalkyl for example CF 3 or CH 2 CF 3
  • OCF 3 OCF 3
  • R 8 ) P CN for example CN
  • (CH 2 ) p —N(R 5 )—S(O) 2 R 8 for example NHSO 2 CH 3 and SO 2 R 9 , for example SO 2 CH 3
  • Y is substituted by one or more groups selected from OR 5 , halogen, C 1-6 haloalkyl, and —(CH 2 ) q —N(R 5 )C(O)R 8 .
  • Y is substituted by one or more groups selected from halogen, and C 1-4 haloalkyl.
  • X represents A or A1
  • A represents cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocyclyl
  • A1 represents —CH 2 —O—(CH 2 ) w N(R 5 )C(O)O—, —CH 2 —N(R 5 )C(O)O—, —CH 2 —N(R 5 )C(O)—, —CH 2 —(O) p —(CH 2 ) q C(O)NR 5 —, —CH 2 —N(R 5 )C(O)N(R 5 )—, or —CH 2 —C(O)N((CH 2 ) m OH)—
  • Y represents a ring, for example when X represents oxadizolyl, tetrazolyl or pyrazolyl and Y represents phenyl, pyridinyl, or thienyl, m
  • R 2 represents C 1-10 alkyl which may be optionally substituted by one or more of: cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1-6 haloalkyl, halogen, —CN, —OR 4 , —(CH 2 ) n COR 5 , —C(O)OR 4 , —OCOR 4 , —(CH 2 ) n NR 5 R 5 , and —(NH) p CONR 5 R 6 .
  • R 2 is selected from C 1-10 alkyl which may be optionally substituted by one or more of: cycloalkyl, aryl, heteroaryl, C 1-6 haloalkyl, halogen, —CN, —OR 4 , —(CH 2 ) n COR 5 , —C(O)OR 4 and —OCOR 4 .
  • R 2 is selected from C 1-6 alkyl which may be optionally substituted by one or more of: cycloalkyl, C 1-6 haloalkyl, halogen, —CN or —OR 4 .
  • R 2 is selected from C 3-6 alkyl, for example butyl or pentyl.
  • R 3 represents halogen. In a further embodiment, R 3 is selected from: chlorine and bromine. In another embodiment, R 3 represents chlorine.
  • the compounds of formula (I) may have one or more asymmetric carbon atom and may occur as recemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.
  • a compound of formula (I) contains an alkenyl or alkenylene group
  • cis (E) and trans (Z) isomerism may also occur.
  • the present invention includes the individual stereoisomers of the compound of the invention and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.
  • Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or HPLC of a stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as HPLC of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.
  • crystalline forms of the compounds of formula (I) may exist as polymorphs, which are included in the present invention.
  • One form may have an advantage over another form, for example one form may have improved stability over another form.
  • alkyl refers to a straight or branched hydrocarbon chain unless specified otherwise, containing the specified number of carbon atoms.
  • C 3 -C 10 alkyl means a straight or branched hydrocarbon chain containing at least 3 and at most 10 carbon atoms.
  • alkyl as used herein include, but are not limited to methyl (Me), ethyl (Et), n-propyl and i-propyl.
  • alkylene or as used herein means both straight and branched chain, or cyclic saturated hydrocarbon linker groups.
  • alkylene groups include methylene (—CH 2 —), ethylene (—CH 2 CH 2 —), ethene (—CH ⁇ CH—), or cyclopropylene and the like.
  • -(alk) n -, where n is 3 represents —(CH 2 ) 3 —, —C(CH 3 ) 2 —, —CH 2 CH ⁇ CH—, or -cyclopropylene- and the like.
  • -(alk) m - where m is 4 represents —(CH 2 ) 4 —, —CH 2 C(CH 3 ) 2 —, —CH 2 CH ⁇ CHCH 2 —, or —CH 2 cyclopropylene- and the like.
  • alkenyl refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms which contains one or more double bonds.
  • alkynyl refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms which contains one or more triple bonds.
  • cycloalkyl refers to a saturated monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl and the like.
  • cycloalkylene refers to a saturated monocyclic hydrocarbon ring of 3 to 8 carbon linker groups. Examples of such groups include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene or cyclooctylene and the like.
  • cycloalkenyl refers to an unsaturated non-aromatic monocyclic hydrocarbon ring of 3 to 8 carbon atoms containing one or more carbon-carbon double bonds. Examples of such groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl or cyclooctenyl and the like.
  • cycloalkenylene refers to an unsaturated non-aromatic monocyclic hydrocarbon ring of 3 to 8 carbon linker groups containing one or more carbon-carbon double bonds. Examples of such groups include cyclopropenylene, cyclobutenylene, cyclopentenylene, cyclohexenylene, cycloheptenylene or cyclooctenylene and the like.
  • aryl refers to a C 6-12 monocyclic, bicyclic or tricyclic hydrocarbon ring wherein at least one ring is aromatic. Examples of such groups include phenyl, naphthyl or tetrahydronaphthalenyl and the like.
  • heteroaryl refers to a 5-6 membered monocyclic aromatic ring or a fused 8-10 membered bicyclic aromatic ring, containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur. There may be one or more optional oxo substituents on the ring carbon atoms.
  • Examples of such monocyclic aromatic rings include thienyl, furyl, furazanyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, pyridyl, triazinyl, tetrazinyl and the like.
  • fused aromatic rings include quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, pteridinyl, cinnolinyl, phthalazinyl, naphthyridinyl, indolyl, isoindolyl, azaindolyl, indolizinyl, indazolyl, purinyl, pyrrolopyridinyl, furopyridinyl, benzofuranyl, isobenzofuranyl, benzothienyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like.
  • heterocyclyl refers to a 4-7 membered monocyclic ring or a fused 8-12 membered bicyclic ring which may be saturated or partially unsaturated containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur. There may be one or more optional oxo substituents on the ring carbon atoms.
  • Examples of such monocyclic rings include pyrrolidinyl, azetidinyl, pyrazolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, dioxolanyl, dioxanyl, oxathiolanyl, oxathianyl, dithianyl, dihydrofuranyl, tetrahydrofuranyl, dihydropyranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, diazepanyl, azepanyl and the like.
  • bicyclic rings examples include indolinyl, isoindolinyl, benzopyranyl, quinuclidinyl, 2,3,4,5-tetrahydro-1H-3-benzazepine, tetrahydroisoquinolinyl and the like.
  • 3 or 4 ring fused system refers to a fused 12-18 membered tricyclic or tetracyclic ring which contains 1 to 4 heteroatoms of N and wherein at least one ring is aromatic. There may be one or more optional oxo substituents on the ring carbon atoms. Examples of such fused aromatic rings include carbazolyl, acenaphthyl, naphthotriazolyl and the like.
  • halogen or “halo” as used herein refer to a fluorine, chlorine, bromine or iodine atom.
  • C 1-6 haloalkyl refers to a C 1-6 alkyl group as defined herein wherein at least one hydrogen atom is replaced with halogen. Examples of such groups include fluoroethyl, trifluoromethyl or trifluoroethyl and the like.
  • pharmaceutically acceptable derivative refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, salts, solvates or esters, which upon administration to a mammal, such as a human, is capable of providing (directly or indirectly) such a compound or an active metabolite thereof.
  • pharmaceutically acceptable derivative refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, salts, solvates or esters, which upon administration to a mammal, such as a human, is capable of providing (directly or indirectly) such a compound or an active metabolite thereof.
  • Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1: Principles And Practice, which is incorporated herein by reference.
  • the term “pharmaceutically acceptable” used in relation to an ingredient (active ingredient, diluent, excipient or carrier) which may be included in a pharmaceutical formulation for administration to a patient refers to that ingredient being acceptable in the sense of being compatible with any other ingredients present in the pharmaceutical formulation and not being deleterious to the recipient thereof.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a pharmaceutically acceptable derivative thereof) and a solvent.
  • solvents for the purposes of the present invention may not interfere with the biological activity of the solute.
  • the solvent used may be a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid.
  • An example of a solvent that may be used is water, in which case the solvate may be referred to as a hydrate of the solute in question.
  • salt or solvate referred to above will be a pharmaceutically acceptable salt or solvate.
  • other salts or solvates may find use, for example, in the preparation of a compound of formula (I) or in the preparation of a pharmaceutically acceptable salt or solvate thereof.
  • Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19.
  • Suitable pharmaceutically acceptable salts include alkali metal salts formed from the addition of alkali metal bases such as alkali metal hydroxides. Examples of suitable alkali metal salts include sodium salts and potassium salts.
  • Other suitable pharmaceutically acceptable salts include alkaline earth metal salts such as calcium salts and magnesium salts, ammonium salts; or salts with organic bases such as ethanolamine, triethanolamine, ethylene diamine, triethylmine, choline and meglumine; or salts with amino acids such as arginine, lysine and histidine.
  • Esters may be active in their own right and/or be hydrolysable under in vivo conditions in the human body. Suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt. An ester may be formed at a carboxylic acid (—C(O)OH) group, by methods well known in the art involving reaction with the corresponding alcohol.
  • esters may be C 1-6 alkyl esters, e.g. methyl esters, ethyl esters, and the like.
  • the term “compounds of the invention” means the compounds according to Formula I and the pharmaceutically acceptable derivatives thereof.
  • the term “a compound of the invention” means any one of the compounds of the invention as defined above.
  • At least one chemical entity means at least one chemical substance chosen from the group of compounds consisting of compounds of formula I and pharmaceutically acceptable derivatives thereof.
  • Theta diffraction anglet account for positions of various peaks in the X-ray diffraction pattern. Slight variations in observed 2 theta angles are expected based on the specific diffractometer employed and the analyst's sample preparation technique.
  • the substantially crystalline forms of 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione can be identified by the presence of a characteristic 2 theta angle peak, or by multiple 2 theta angles which are reasonably characteristic of the particular crystalline forms.
  • At least one of the foregoing 2 theta angles are employed to identify substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione form 1 and substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione form 2.
  • At least 2, 3, 4 or 5 (where applicable) of the foregoing 2 theta angles are employed to identify substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione form 1, substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione form 2.
  • margin of error is present in each of the 2 theta angle assignments.
  • the margin of error in the foregoing 2 theta angles is approximately ⁇ 0.1 degrees for each of the foregoing peak assignments.
  • the preferred method of comparing X-ray powder diffraction patterns in order to identify a particular crystalline form is to overlay the X-ray powder diffraction pattern of the unknown form over the X-ray powder diffraction pattern of a known form.
  • one skilled in the art can overlay an X-ray powder diffraction pattern of an unidentified form of 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione, obtained using the methods described herein, see FIG.
  • substantially crystalline form means that it is substantially free of amorphous form 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione.
  • substantially free is meant containing less than 50% of the amorphous form, in one aspect less than 20% of the amorphous form, in another aspect less than 10% of the amorphous form, in another aspect less than 5% of the amorphous form, in another aspect less than 2% of the amorphous form, in another aspect less than 1% of the amorphous form.
  • the present invention provides a method for the preparation of substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione form as described herein.
  • Compounds of formula (I) are of potential therapeutic benefit in the treatment and amelioration of the symptoms of many diseases of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke.
  • Inflammation represents a group of vascular, cellular and neurological responses to trauma. Inflammation can be characterised as the movement of inflammatory cells such as monocytes, neutrophils and granulocytes into the tissues. This is usually associated with reduced endothelial barrier function and oedema into the tissues. Inflammation with regards to disease typically is referred to as chronic inflammation. Such chronic inflammation may manifest itself through disease symptoms. The aim of anti-inflammatory therapy is therefore to reduce this chronic inflammation and allow for the physiological process of healing and tissue repair to progress.
  • inflammatory diseases or conditions for which the compounds of the present invention may demonstrate utility include those of the joint, for example arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the lung (e.g. adult respiratory distress syndrome, asthma, cystic fibrosis, or chronic obstructive pulmonary disease), of the heart (e.g. myocarditis), of nervous tissue (e.g. multiple sclerosis), of the pancreas, (e.g.
  • arthritis e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure
  • the gastrointestinal tract e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation
  • kidney e.g. glomerulonephritis
  • the skin e.g. dermatitis, psoriasis, eczema, urticaria, burn injury
  • the eye e.g. glaucoma
  • transplanted organs e.
  • the compounds of this invention are useful in the treatment and prevention of inflammation, diabetes and cardiovascular diseases or conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidaemia.
  • Nicotinic acid has a significant side effect profile, possibly because it is dosed at high level (gram quantities daily). The most common side effect is an intense cutaneous flushing.
  • the compounds may exhibit reduced side effects compared to nicotinic acid.
  • HM74A has been identified as a high affinity receptor for nicotinic acid whilst HM74 is a lower affinity receptor.
  • the compounds of the present invention show greater affinity for HM74A than for HM74 therefore may find use as selective HM74A agonists or partial agonists.
  • HM74A The potential for compounds of formula (I) to activate HM74A may be demonstrated, for example, using the following in vitro whole cell assays:
  • HEK293T cells HEK293 cells stably expressing the SV40 large T-antigen
  • DMEM fetal calf serum
  • 2 mM glutamine 10% foetal calf serum
  • Cells were seeded in 90 mm culture dishes and grown to 60-80% confluence (18-24 h) prior to transfection.
  • Human HM74A GenBankTM accession number AY148884
  • Human HM74A was subcloned in to a mammalian expression vector (pcDNA3; Invitrogen) and transfected using Lipofectamine reagent.
  • CHO-K1 cells For generation of stable cell lines the above method was used to transfect CHO-K1 cells seeded in six well dishes grown to 30% confluence. These cells were maintained in DMEM F-12 HAM media containing 10% foetal calf serum and 2 mM glutamine. 48 h post-transfection the media was supplemented with 400 ⁇ g/ml Geneticin (G418, Gibco) for selection of antibiotic resistant cells. Clonal CHO-K1 cell lines stably expressing HM74A were confirmed by [ 35 S]-GTP ⁇ S binding measurements, following the addition of nicotinic acid.
  • P2 membrane preparation Plasma membrane-containing P2 particulate fractions were prepared from cell pastes frozen at ⁇ 80° C. after harvest. All procedures were carried out at 4° C. Cell pellets were resuspended in 1 ml of 10 mM Tris-HCl and 0.1 mM EDTA, pH 7.5 (buffer A) and by homogenisation for 20 s with a Ultra Turrax followed by passage (5 times) through a 25-gauge needle. Cell lysates were centrifuged at 1,000 g for 10 min in a microcentrifuge to pellet the nuclei and unbroken cells and P2 particulate fractions were recovered by microcentrifugation at 16,000 g for 30 min. P2 particulate fractions were resuspended in buffer A and stored at ⁇ 80° C. until required.
  • [ 35 S]-GTP ⁇ S binding—assays were performed at room temperature in 384-well format based on methods described previously, (Wieland, T. and Jakobs, K. H. (1994) Methods Enzymol. 237, 3-13). Briefly, the dilution of standard or test compounds were prepared and added to a 384-well plate in a volume of 10 ⁇ l.
  • Membranes (HM74A or HM74) were diluted in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl 2 , pH7.4) supplemented with saponin (60 ⁇ g/ml), Leadseeker WGA beads (Amersham; 250 ⁇ g/well) and 10 ⁇ M GDP, so that the 20 ⁇ l volume added to each well contains 5 ⁇ g of membranes.
  • [ 35 S]-GTP ⁇ S (1170 Ci/mmol, Amersham) was diluted (1:1500) in assay buffer and 20 ⁇ l added to each well. Following the addition of the radioligand, the plates were sealed, pulse spun and incubated for 4 hours at room temperature. At the end of the incubation period the plates were read on a Leadseeker machine (VIEWLUX PLUS; Perkin-Elmer) to determine the levels of specific binding.
  • HM74A agonists can be tested in male Spague-Dawley rats (200-250 g) which have been fasted for at least 12 hours prior to the study.
  • the compounds are dosed intravenously at either 1 or 3 mg/kg (5 ml/kg) or by oral gavage at doses ranging from 1-30 mg/kg (10 ml/kg).
  • Blood samples (0.3 ml tail vein bleed) can be taken pre-dose and at three times post-dose (times ranging from 15 minutes to 6 hours post-dose). Each blood sample is transferred to a heparin tube (Becton Dickinson Microtainer, PST LH) and centrifuged (10,000 g for 5 minutes) to produce a plasma sample.
  • heparin tube Becton Dickinson Microtainer, PST LH
  • NEFA non-esterified fatty acids
  • HM74A compounds exhibit the flushing response associated with nicotinic acid they can be dosed to conscious guinea-pigs.
  • Pre-study blood samples 0.5 ml are taken from each animal by cardiac puncture under recovery anaesthesia (Isoflurane 3.5% with additional O2 (1 L/min)).
  • Ear temperature measurements are taken by placing the left ear of each animal over an infra-red temperature probe. Measurements are taken at one minute intervals from 5 minutes pre-dose to 30 minutes post-dose.
  • Temperature measurements are then taken at 15 minute intervals up to 2 hours post-dose. Animals receive test compounds by oral gavage (5 ml/kg). Blood samples (0.5 ml) are taken by cardiac puncture under terminal anaesthesia. Blood samples are taken from individual animals to provide data at 0.5, 1, 2, 3, and 4 hours post-dose. All blood samples are placed on a blood roller for 5 minutes then stored on ice until the end of the study. Following centrifugation (12000 g for 5 min) the plasma is transferred into fresh tubes and stored at ⁇ 20° C. until assayed for NEFA concentrations.
  • the exemplified compounds (Examples 1-894) have a pEC 50 of 4.3 (+/ ⁇ 0.3 log unit) or greater and an efficacy of 30% or greater (in relation to nicotinic acid) in the [ 35 S]-GTP ⁇ S binding assays described above, in which they were tested.
  • MS mass spectra
  • BiotageTM chromatography refers to purification carried out using either the Flash 40i or Flash 150i purification systems, sold by Biotage AB, using cartridges pre-packed with KPSil (silica).
  • CompanionTM system refers to the Teledyne Isco Combiflash CompanionTM purification system. This is a gradient controlled purification system with integral, variable wavelength UV detection with the capability to trigger automated fraction collection by UV threshold.
  • Mass directed autoprep refers to methods where the material was purified by high performance liquid chromatography using either a Supelcosil ABZ+5 ⁇ m column (10 cm ⁇ 20 mm i.d.) or a Supelcosil ABZ+10 ⁇ m column (15 cm ⁇ 30 mm i.d.) with a suitable gradient of solvent A: 0.1% HCO 2 H in water and solvent B: 95% MeCN, 5% water (containing 0.5% HCO 2 H).
  • the Waters 2767 inject/collector was triggered by a MicroMass ZQ Mass Spectrometer on detecting the mass of interest (using Micromass MassLynx software).
  • Preparative HPLC (Autoprep HPLC or Autoprep) refers to methods where the material was purified by high performance liquid chromatography on a Supelcosil ABZ+5 ⁇ m column (10 cm ⁇ 21.2 mm i.d.) with a suitable gradient of 0.1% HCO 2 H in water and MeCN (with 0.5% HCO 2 H).
  • the Gilson 233 fraction collector was triggered by UV detection.
  • SPE solid phase extraction
  • C18 SPE refers to the use of cartridges pre-packed with 40 ⁇ M C18 funtionalised silica sorbent (sold by Varian Inc.). The compound was loaded, typically in 50:50 DMSO/MeOH, onto a cartridge previously conditioned with MeCN and equilibrated with 5% MeCN in water. The product was eluted with a suitable gradient of 0.1% HCO 2 H in water and MeCN (0.5% HCO 2 H).
  • Aminopropyl SPE or column refers to the use of cartridges pre-packed with 40 ⁇ m-120 ⁇ m aminopropyl functionalized silica (sold by Varian Inc.).
  • the crude product is typically loaded in DCM/MeOH mixtures onto a cartridge previously conditioned with MeOH.
  • the neutral components were eluted with MeOH and/or DCM (3 or 4 column volumes) and the acidic components usually eluted with an eluent containing a proportion of AcOH (2-20%).
  • OasisTM Cartridges/OasisTM SPE's refer to SPE cartridges packed with a polymeric sorbent manufactured by the Waters Corporation. These are typically conditioned with 3 column volumes of MeOH and equilibrated with water before the sample is loaded. Salts and inorganics are eluted with water and the product typically eluted with MeOH or MeCN.
  • GreenHouseTM refers to a 24 reaction parallel synthesiser platform available from RDT Ltd, UK
  • compounds of Formula (I) may find use in human or veterinary medicine, for example as activators of HM74A, in the management of dyslipidaemia and hyperlipoproteinaemia.
  • At least one compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine, for example in the treatment of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa and obesity.
  • the compounds are also provided for use in the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke.
  • At least one compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • the compounds are also provided for use in the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke.
  • references herein to treatment extend to prophylaxis, prevention of recurrence and suppression of symptoms as well as the treatment of established conditions.
  • At least one compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia for use in the treatment of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia.
  • the use is provided of at least one compound of Formula (I) or a pharmaceutically acceptable derivative thereof in the treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesteraemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, stroke and cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • the present invention provides the use of at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of inflammatory diseases or conditions of the joint, for example, arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or of the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the lung (e.g. adult respiratory distress syndrome, asthma, cystic fibrosis, or chronic obstructive pulmonary disease), of the heart (e.g.
  • arthritis e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure
  • the gastrointestinal tract e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the
  • myocarditis of nervous tissue (e.g. multiple sclerosis), of the pancreas, (e.g. inflammation associated with diabetes melitus and complications thereof, of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, eczema, urticaria, burn injury), of the eye (e.g. glaucoma) as well as of transplanted organs (e.g. rejection) and multi-organ diseases (e.g.
  • systemic lupus erythematosis, sepsis systemic lupus erythematosis, sepsis
  • a method for the treatment of a human or animal subject with a condition where under-activation of the HM74A receptor contributes to the condition or where activation of the receptor will be beneficial comprises administering to said human or animal subject an effective amount of at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • the present invention provides a method for the treatment of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa and obesity, which method comprises administering to said human or animal subject an effective amount of at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • dyslipidaemia and hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia
  • cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia
  • type II diabetes mellitus type I diabetes
  • insulin resistance hyperlipidaemia
  • anorexia nervosa anorexia nervosa and obesity
  • these compounds may also find favour in methods for the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, which methods comprise administering to said human or animal subject an effective amount of at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • the amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof which is required to achieve the desired biological effect will, of course, depend on a number of factors, for example, the mode of administration and the precise clinical condition of the recipient.
  • the daily dose will be in the range of 0.1 mg-1-g/kg, typically 0.1-100 mg/kg.
  • An intravenous dose may, for example, be in the range of 0.01 mg to 0.1 g/kg, typically 0.01 mg to 10 mg/kg, which may conveniently be administered as an infusion of from 0.1 ⁇ g to 1 mg, per minute.
  • Infusion fluids suitable for this purpose may contain, for example, from 0.01 ⁇ g to 0.1 mg, per millilitre.
  • Unit doses may contain, for example, from 0.01 ⁇ g to 1 g of a compound of the invention.
  • ampoules for injection may contain, for example, from 0.01 ⁇ g to 0.1 g and orally administrable unit dose formulations, such as tablets or capsules, may contain, for example, from 0.1 mg to 1 g, for example from 5 mg to 50 mg.
  • a compound of formula (I) or a pharmaceutically acceptable derivative thereof may be employed as the compound per se in the treatment of a disease where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, an example of this is where a compound of the present invention is presented with an acceptable carrier in the form of a pharmaceutical formulation.
  • the carrier must, of course, be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient.
  • the carrier may be a solid or a liquid, or both, and may be formulated with the compound of the invention as a unit-dose formulation, for example, a tablet, which may contain from 0.05% to 95% by weight of the compound of the invention.
  • the formulations include those suitable for oral, rectal, topical, buccal (e.g. sub-lingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration.
  • buccal e.g. sub-lingual
  • parenteral e.g. subcutaneous, intramuscular, intradermal or intravenous
  • Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges or tablets, each containing a predetermined amount of a a compound of formula (I) or a pharmaceutically acceptable derivative thereof; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • the formulations are prepared by uniformly and intimately admixing the compound of formula (I) or a pharmaceutically acceptable derivative thereof, with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product.
  • a tablet may be prepared by compressing or moulding a powder or granules of the compound of formula (I) or a pharmaceutically acceptable derivative thereof optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s).
  • Moulded tablets may be made by moulding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid.
  • the preparations may also contain buffer salts, flavouring,
  • Formulations of the present invention suitable for parenteral administration conveniently comprise sterile aqueous preparations of a compound of formula (I) or a pharmaceutically acceptable derivative thereof, the formulation may be isotonic with the blood of the intended recipient. These preparations could be administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the compound of formula (I) or a pharmaceutically acceptable derivative thereof with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the invention will generally contain from 0.1 to 5% w/w of the compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • formulations of the present invention suitable for parenteral administration comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof may be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi-dose containers with an added preservative.
  • the compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or toxicity adjusting agents.
  • formulations suitable for oral administration include formulations comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof, in 10% DMSO and 90% sodium hydrogen carbonate in sterile saline.
  • formulations suitable for intravenous administration include formulations comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof, in 5% or 10% DMSO and 95% or 90% sodium hydrogen carbonate in sterile water.
  • the therapeutically active agent may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • the dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.
  • Formulations suitable for rectal administration may be presented as unit-dose suppositories. These may be prepared by admixing a a compound of formula (I) or a pharmaceutically acceptable derivative thereof with one or more conventional solid carriers, for example, cocoa butter or glycerides and then shaping the resulting mixture.
  • a a compound of formula (I) or a pharmaceutically acceptable derivative thereof with one or more conventional solid carriers, for example, cocoa butter or glycerides and then shaping the resulting mixture.
  • Formulations suitable for topical application to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which may be used include vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof.
  • the compound of formula (I) or a pharmaceutically acceptable derivative thereof is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to 2%.
  • topical administration as used herein, we include administration by insufflation and inhalation.
  • preparation for topical administration include ointments, creams, lotions, powders, pessaries, sprays, aerosols, capsules or cartridges for use in an inhaler or insufflator or drops (e.g. eye or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents and/or solvents.
  • bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil or a solvent such as a polyethylene glycol.
  • Thickening agents which may be used include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, microcrystalline wax and beeswax.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.
  • Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.
  • Spray compositions may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,2-tetrafluorethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,2-tetrafluorethane, carbon dioxide or other suitable gas.
  • Capsules and cartridges for use in an inhaler or insufflator, of for example gelatin may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • compositions according to the invention may also be used in combination with other therapeutic agents, for example in combination with other classes of dyslipidaemic drugs (e.g. statins, fibrates, bile-acid binding resins or nicotinic acid).
  • dyslipidaemic drugs e.g. statins, fibrates, bile-acid binding resins or nicotinic acid.
  • the compounds of the instant invention may be used in combination with one or more other therapeutically active agents for example in combination with other classes of dyslipidaemic drugs e.g. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates or bile acid binding resins or nicotinic acid.
  • dyslipidaemic drugs e.g. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates or bile acid binding resins or nicotinic acid.
  • the invention thus provides, in a further embodiment, the use of such a combination in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial and the use of at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the combination therapy of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa and obesity.
  • disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type
  • the compounds of the present invention are used in combination with other therapeutically active agents, the compounds may be administered either together or separately, sequentially or simultaneously by any convenient route.
  • compositions comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further embodiment of the invention.
  • the individual components of such combinations may be administered either together or separately, sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the two components When combined in the same formulation it will be appreciated that the two components must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.
  • each component When in combination with a second therapeutic agent active against the same disease, the dose of each component may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
  • the invention thus provides, in a further embodiment, a combination comprising at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof together with another therapeutically active agent.
  • the compounds of the present invention and pharmaceutically acceptable derivatives thereof may be prepared by the methodology described hereinafter, constituting a further embodiment of this invention.
  • L represents a leaving group, for example halogen
  • d represents (m ⁇ 1)
  • R represents -(alk) n -Y.
  • L represents a leaving group, for example halogen
  • d represents (m ⁇ 1)
  • R represents —NR 5 R 7 or —OR 5 .
  • L represents a leaving group, for example halogen
  • d represents (m ⁇ 1)
  • R represents -(alk) n -Y.
  • L represents a leaving group, for example halogen
  • d represents (m ⁇ 1)
  • R represents an alkyl group
  • R′ represents -(alk) n -Y.
  • L represents a leaving group, for example halogen
  • d represents (m ⁇ 1)
  • R represents an alkyl group
  • R′ represents -(alk) n -Y.
  • a process according to the invention for preparing compound(s) of formula (I) in which R 3 is CN comprises steps (i) and (ii) of Process 1 followed by:
  • a process according to the invention for preparing compound(s) of formula (I) in which R 3 is Cl or Br comprises steps (i) to (iv) of Process 8 followed by:
  • a process according to the invention for preparing compound(s) of formula (I) in which R 3 is CN comprises steps (i) to (iv) of Process 8 followed by:
  • a process according to the invention for preparing compound(s) of formula (I) in which R 3 is Cl comprises:
  • a process according to the invention for preparing compound(s) of formula (I) in which R 1 differs from R 2 and R 3 is Cl comprises steps (i) to (v) of Process 1 (where R 2 from process 1 is specifically SEM or MEM) followed by:
  • a process according to the invention for preparing compound(s) of formula (I) in which R 3 is Cl, Br or I comprises steps (i) to (iv) of Process 8 followed by:
  • a process according to the invention for preparing compound(s) of formula (I) comprises:
  • L represents a leaving group
  • a resultant compound of formula (I) can be converted into a pharmaceutically acceptable salt form or vice versa or converting one salt form into another pharmaceutically acceptable salt form.
  • FIG. 1 XRPD data of substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione form 1.
  • FIG. 2 XRPD data of substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione form 2.
  • FIG. 3 Overlay of XRPD data for substantially crystalline 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione Form 1 and Form 2.
  • Tetrakis(triphenylphosphine)palladium(0) (16 mg, 0.014 mmol) and morpholine (0.12 ml, 1.35 mmol) were added to the mixture which was stirred for 16 h under a stream of nitrogen.
  • the reaction mixture was concentrated under nitrogen and the crude material dissolved in aqueous NaOH solution (0.5 ml, 2M).
  • the resulting solution was purified using aminopropyl SPE (eluting with AcOH in DCM and MeOH). Further purification using C18 SPE (eluting with a water, ammonia and MeCN mixture) afforded the title compound as a clear gum (22 mg, 45%).
  • the mixture was degassed and stirred with tetrakis(triphenylphosphine)palladium(0) (46 mg, 0.04 mmol) and morpholine (176 mg, 2 mmol) at rt for 6 h.
  • the reaction was worked up and purified by aminopropyl SPE (5 g, washing with THF-MeOH (1:1) then neat MeOH, eluting with DCM-MeOH (1:1) with 5% added AcOH) to yield the title compound (37.7 mg) as a solid.
  • the crude was purified by a silica SPE column using a 0.5-5% MeOH/DCM gradient. The product fractions were combined and concentrated under high vacuum. The product was dissolved in THF (5 ml) then Pd(PPh 3 ) 4 (88 mg, 0.077 mmol) and morpholine (670 ⁇ l, 7.67 mmol) were added and the mixture left to stir at rt under nitrogen for 3 h. 88 mg of Pd(PPh 3 ) 4 (0.077 mmol) was added and the mixture was left to stir at rt under nitrogen for 16 h. The mixture was partitioned between EtOAc and H 2 O. The organic layer was separated and the aqueous layer was extracted with EtOAc ( ⁇ 2). The organic layers were combined, washed with brine, dried (MgSO 4 ) and concentrated. The crude product was purified by MDAP to give the title compound as a white solid (9 mg, 2%).
  • the organic layer was separated, washed with brine, dried (MgSO 4 ) and concentrated.
  • the crude product was purified on a silica SPE column using a DCM to load the material onto the column and wash through the impurities then a 0-5% MeOH/DCM gradient to elute the compound.
  • the product fractions were combined and concentrated and the residues dissolved in anhydrous DMF (3 ml).
  • the solution was degassed then Pd(PPh 3 ) 4 (39 mg, 0.034 mmol) and morpholine (200 ⁇ l, 2.3 mmol) were added and the mixture left to stir at rt under nitrogen for 3 h.
  • the crude product was purified by an aminopropyl SPE using MeOH to load the compound onto the column and wash through the impurities then a 0-5% AcOH/MeOH gradient to elute the product.
  • the product fractions were combined and concentrated by high vacuum to leave the title compound as a white solid (14 mg, 7%).
  • the organic layer was separated, washed with brine, dried (MgSO 4 ) and concentrated.
  • the crude product was purified on a silica SPE column using DCM to load the material onto the column and wash through the impurities then a 0-5% MeOH/DCM gradient to elute the compound.
  • the product fractions were combined and concentrated and the residues dissolved in anhydrous DMF (3 ml).
  • the solution was degassed then Pd(PPh 3 ) 4 (35 mg, 0.030 mmol) and morpholine (174 ⁇ l, 2.0 mmol) were added and the mixture left to stir at rt under nitrogen for 3 h.
  • the crude product was purified by an aminopropyl SPE using MeOH to load the compound onto the column and wash through the impurities then a 0-5% AcOH/MeOH gradient to elute the product.
  • the product fractions were combined and concentrated by high vacuum to leave the title compound as a white solid (50 mg, 26%).
  • the organic layer was separated, washed with brine, dried (MgSO 4 ) and concentrated.
  • the crude product was purified on a silica SPE column using a DCM to load the material onto the column and wash through the impurities then a 0-5% MeOH/DCM gradient to elute the compound.
  • the product fractions were combined and concentrated and the residues dissolved in anhydrous DMF (3 ml).
  • the solution was degassed then Pd(PPh 3 ) 4 (30 mg, 0.027 mmol) and morpholine (156 ⁇ l, 1.8 mmol) were added and the mixture left to stir at rt under nitrogen for 3 h.
  • the crude product was purified by an aminopropyl SPE using MeOH to load the compound onto the column and wash through the impurities then a 0-5% AcOH/MeOH gradient to elute the product.
  • the product fractions were combined and concentrated by high vacuum to leave the title compound as a white solid (18 mg, 9%).
  • Example 3 The compounds in Table 3 were prepared using a method analogous to that for Example 36: 8-chloro-1-(3- ⁇ 5-[(4-fluorophenyl)methyl]-2H-tetrazol-2-yl ⁇ propyl)-3-(4,4,4-trifluorobutyl)-3,7-dihydro-1H-purine-2,6-dione, with the appropriate methanesulfonate and tetrazole. MDAP was employed to further purify those compounds insufficiently pure following normal phase chromatography.
  • Methanesulfonates intermediates and their precursor alcohols were prepared according to the following procedures:
  • the organic layer was separated, washed with brine, dried (MgSO 4 ) and concentrated.
  • the crude product was purified by a silica SPE column using a 0-70% cyclohexane/EtOAc gradient.
  • the product fractions were combined, concentrated and further purified by a silica SPE column using a 0-60% cyclohexane/EtOAc gradient.
  • the product fractions were combined and concentrated then dissolved in anhydrous THF (4 ml).
  • the solution was degassed by high vacuum then Pd(PPh 3 ) 4 (86 mg, 0.074 mmol) and morpholine (644 ⁇ l, 7.4 mmol) were added and the mixture left to stir at rt under nitrogen for 1 day.
  • the mixture was partitioned between EtOAc and HCl (aq). The organic layer was separated, washed with brine, dried (MgSO 4 ) and concentrated by high vacuum.
  • the crude product was purified by an aminopropyl SPE using MeOH to load the compound onto the column and wash through the impurities then a 2-4% AcOH/MeOH gradient to elute the product.
  • the product fractions were combined and concentrated by high vacuum to leave the title compound as a white solid (74 mg, 23%).
  • Morpholine (14.9 g, 171 mmol) was added followed by tetrakis(triphenylphosphine)palladium(0) (4.0 g, 3.46 mmol) and the mixture was stirred for 4 h.
  • EtOAc 300 ml
  • 2M HCl 150 ml
  • water 100 ml
  • the filtrate was dried (Na 2 SO 4 ) and evaporated.
  • the crude product (10 g) was purified by aminopropyl SPE (3 ⁇ 20 g), loading in THF/MeOH (1:1), washing with THF/MeOH (1:1) and neat MeOH and eluting the product with DCM/MeOH (1:1) containing 5% added AcOH to afford the title compound (5.08 g).
  • Example 4 The following compounds (Table 4) were prepared using a method analogous to that for Example 96, using the appropriate amidoxime, (with the exceptions that for Example 110 (Table 4) during workup the pH was adjusted to 5 prior to extraction with EtOAc; and in the case of Example 111 (Table 4) the crude product was stirred for 18 h with EtOH (1 ml) and 2M NaOH (0.5 ml) and Example 112 (Table 4) was stirred for 18 h with EtOH (0.75 ml) and 2M NaOH (0.5 ml) prior to repeat workup and purification by MDAP).
  • Example 5 The following compounds (Table 5) were prepared using a method analogous to that for Example 114, using the appropriate amidoxime (with the exception that for Example 115 and Example 125, 0.185 ml, (0.5 mmol) of 21% sodium ethoxide was added in order to allow for the amidoximes being the hydrochloride salts).
  • Example 6 The following compounds (Table 6) were prepared using a method analogous to that for Example 126, using the appropriate amidoxime (with the exception that for Example 127 (Table 6), the crude product after workup was stirred with EtOH (1 ml) and 2M NaOH (0.5 ml) overnight in order to hydrolyse residual starting ester, prior to repeat HCl workup and purification by MDAP).
  • the organic layer was separated, washed with brine, dried (MgSO 4 ) and concentrated by high vacuum.
  • the crude product was purified on a silica SPE column using a 0-70% cyclohexane/EtOAc gradient.
  • the product fractions were combined, concentrated by high vacuum and purified on a silica SPE column using a 0-60% cyclohexane/EtOAc gradient.
  • the product fractions were combined and concentrated then dissolved in anhydrous THF (4 ml).
  • the mixture was heated at 40° C. for 1 h, then at 80° C. for 5 h and then cooled.
  • the mixture was subjected to purification by MDAP.
  • Product-containing fractions were blown to dryness by a stream of nitrogen to yield the title compound as a white solid (17.2 mg, 25%).
  • a 12-L, round-bottom flask was equipped with an overhead, mechanical stirrer, a temperature probe with a J-KEM temperature controller, a condenser and a nitrogen inlet adapter.
  • the flask was charged with picolinic acid (0.180 kg, 1.46 mol), MIBK (4.0 L), 1,1′-carbonyldiimidazole (0.23 kg, 1.42 mol) and more MIBK (0.66 L).
  • the mixture was stirred and warmed to 50° C. over approximately 1 hour, and the temperature overshot to 56° C. The solids dissolved during the heat up to 50° C. and carbon dioxide was generated.
  • the reaction vessel was charged with 3-Butyl-8-chloro-1- ⁇ 4-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]butyl ⁇ -3,7-dihydro-1H-purine-2,6-dione (1 wt), acetone (20vol) and water (0.6vol). The mixture was stirred and warmed to 50-60° C. and agitated for a minimum of 1 hour. A solution was formed which is clarified at this temperature by filtration through a 1 micron filter into a 2 nd reaction vessel. The solution was cooled over approximately 3 hours to 33-38° C.
  • the batch is reheated to 35-45° C. and agitated at this temperature for a minimum of 1 hour.
  • the thin suspension is then cooled to 20-25° C. and held at this temperature for a minimum of 12 hours.
  • the suspension thus formed is then cooled to 13-17° C. and held at this temperature for a minimum of 1 hour.
  • the suspension is then sampled, and the solid collected by filtration in the laboratory. The solid is dried and analysed by xrpd/DSC to check form. If the form is as required (Form 1) the batch is filtered, washed and dried as described previously. If the form is not pure Form 1, then the cycle from is repeated until a satisfactory result is obtained.
  • X-ray powder diffraction (XRPD) data are shown in FIGS. 1-3 .
  • the data were acquired on a PANalytical X'Pert Pro powder diffractometer, model PW3040/60, serial number DY1850 using an X'Celerator detector.
  • the acquisition conditions were: radiation: Cu K ⁇ , generator tension: 40 kV, generator current: 45 mA, start angle: 2.0°2 ⁇ , end angle: 40.0°2 ⁇ , step size: 0.0167°2 ⁇ , time per step: 31.75 seconds.
  • the samples were prepared by mounting a few milligrams of sample on a Si wafer (zero background) plates, resulting in a thin layer of powder.
  • 2-Thiophenecarboxylic acid 14 mg, 0.11 mmol was dissolved in NMP (0.9 ml) and treated with CDI (18 mg, 0.11 mmol). After 1 h, (1Z)-5-(8-chloro-2,6-dioxo-3-pentyl-2,3,6,7-tetrahydro-1H-purin-1-yl)-N-hydroxypentanimidamide (50 mg, 0.13 mmol) was added and the mixture heated in the microwave at 150° C. for 15 min. The solution was directly purified by MDAP to obtain the title compound which was then freeze dried from 1,4-dioxane to give the title compound as a white solid (19 mg, 31%).
US12/063,432 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists Abandoned US20100179128A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0516464.5 2005-08-10
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0607736.6 2006-04-19
GB0614569.2 2006-07-21
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
PCT/EP2006/007869 WO2007017262A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Publications (1)

Publication Number Publication Date
US20100179128A1 true US20100179128A1 (en) 2010-07-15

Family

ID=37189397

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/063,434 Expired - Fee Related US8143264B2 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective HM74A agonists
US12/063,432 Abandoned US20100179128A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists
US13/088,962 Abandoned US20110257205A1 (en) 2005-08-10 2011-04-18 Xanthine derivatives as selective hm74a agonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/063,434 Expired - Fee Related US8143264B2 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective HM74A agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/088,962 Abandoned US20110257205A1 (en) 2005-08-10 2011-04-18 Xanthine derivatives as selective hm74a agonists

Country Status (29)

Country Link
US (3) US8143264B2 (pt)
EP (3) EP1912991B1 (pt)
JP (2) JP2009504592A (pt)
KR (2) KR20080034993A (pt)
AR (1) AR055369A1 (pt)
AT (1) ATE487719T1 (pt)
AU (2) AU2006278215A1 (pt)
BR (2) BRPI0614270A2 (pt)
CA (2) CA2618963A1 (pt)
CR (2) CR9749A (pt)
CY (1) CY1111757T1 (pt)
DE (1) DE602006018151D1 (pt)
DK (1) DK1912991T3 (pt)
EA (2) EA200800564A1 (pt)
ES (1) ES2401128T3 (pt)
HK (1) HK1116779A1 (pt)
HR (1) HRP20100725T1 (pt)
IL (2) IL189081A0 (pt)
MA (2) MA29692B1 (pt)
MX (2) MX2008001931A (pt)
MY (1) MY142067A (pt)
NO (2) NO20081212L (pt)
NZ (1) NZ565494A (pt)
PE (1) PE20070405A1 (pt)
PL (1) PL1912991T3 (pt)
PT (1) PT1912991E (pt)
SI (1) SI1912991T1 (pt)
TW (1) TW200800217A (pt)
WO (2) WO2007017261A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100010021A1 (en) * 2004-02-14 2010-01-14 Glaxo Group Limited Novel compounds
US20100168122A1 (en) * 2005-08-10 2010-07-01 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
WO2023150592A3 (en) * 2022-02-03 2023-08-31 D.E. Shaw Research, Llc N3-substituted uracil compounds as trpa1 inhibitors

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE602007010312D1 (de) 2006-06-23 2010-12-16 Incyte Corp Purinonderivate als hm74a-agonisten
EP2044074A2 (en) 2006-06-23 2009-04-08 Incyte Corporation Purinone derivatives as hm74a agonists
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2606045B1 (en) * 2010-08-16 2016-01-06 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
US8580825B2 (en) * 2010-09-23 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201492069A1 (ru) * 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
US9359359B2 (en) * 2013-03-15 2016-06-07 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
WO2014182943A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
CN104211702B (zh) * 2013-05-29 2018-08-31 中国医学科学院药物研究所 取代黄嘌呤类化合物及其制备方法和用途
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US20100099690A1 (en) * 2005-08-10 2010-04-22 Jag Paul Heer Xanthine derivatives as selective hm74a agonists
US20100168122A1 (en) * 2005-08-10 2010-07-01 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
WO1993017684A2 (en) 1992-03-04 1993-09-16 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
CA2183562A1 (en) * 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US6780865B1 (en) * 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
EP1171442B1 (en) 1999-04-09 2005-12-07 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signalling inhibitors
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
EP1404675B1 (en) * 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
KR101100601B1 (ko) * 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
WO2006045565A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
US20080221108A1 (en) * 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
US20100099690A1 (en) * 2005-08-10 2010-04-22 Jag Paul Heer Xanthine derivatives as selective hm74a agonists
US20100168122A1 (en) * 2005-08-10 2010-07-01 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100010021A1 (en) * 2004-02-14 2010-01-14 Glaxo Group Limited Novel compounds
US8268839B2 (en) 2004-02-14 2012-09-18 Glaxosmithkline Llc Compounds
US8394808B2 (en) * 2004-02-14 2013-03-12 Glaxosmithkline Llc HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes
US20100168122A1 (en) * 2005-08-10 2010-07-01 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
US8143264B2 (en) * 2005-08-10 2012-03-27 Glaxosmithkline Llc Xanthine derivatives as selective HM74A agonists
WO2023150592A3 (en) * 2022-02-03 2023-08-31 D.E. Shaw Research, Llc N3-substituted uracil compounds as trpa1 inhibitors

Also Published As

Publication number Publication date
EP1912991B1 (en) 2010-11-10
AU2006278216A1 (en) 2007-02-15
EA014556B1 (ru) 2010-12-30
IL189081A0 (en) 2008-08-07
EA200800555A1 (ru) 2008-08-29
EP1912992A1 (en) 2008-04-23
ATE487719T1 (de) 2010-11-15
KR20080038396A (ko) 2008-05-06
PE20070405A1 (es) 2007-05-06
BRPI0614270A2 (pt) 2011-03-22
DE602006018151D1 (de) 2010-12-23
HRP20100725T1 (hr) 2011-01-31
EP1912991A1 (en) 2008-04-23
JP2009504591A (ja) 2009-02-05
AU2006278215A1 (en) 2007-02-15
MY142067A (en) 2010-08-30
DK1912991T3 (da) 2011-02-21
SI1912991T1 (sl) 2011-03-31
CA2618963A1 (en) 2007-02-15
WO2007017262A1 (en) 2007-02-15
CR9748A (es) 2008-05-05
US8143264B2 (en) 2012-03-27
NZ565494A (en) 2011-06-30
BRPI0615145A2 (pt) 2009-11-03
NO20081212L (no) 2008-05-06
HK1116779A1 (en) 2009-01-02
NO20081211L (no) 2008-05-08
WO2007017261A1 (en) 2007-02-15
MA29692B1 (fr) 2008-08-01
CR9749A (es) 2008-05-22
PT1912991E (pt) 2011-01-17
PL1912991T3 (pl) 2011-04-29
EA200800564A1 (ru) 2008-08-29
CA2626723A1 (en) 2007-02-15
KR20080034993A (ko) 2008-04-22
MX2008001929A (es) 2008-03-24
MX2008001931A (es) 2008-03-24
TW200800217A (en) 2008-01-01
US20110257205A1 (en) 2011-10-20
AR055369A1 (es) 2007-08-22
US20100168122A1 (en) 2010-07-01
CY1111757T1 (el) 2015-10-07
IL189083A0 (en) 2008-08-07
EP2272848B1 (en) 2012-12-26
EP2272848A1 (en) 2011-01-12
ES2401128T3 (es) 2013-04-17
MA29693B1 (fr) 2008-08-01
JP5112316B2 (ja) 2013-01-09
JP2009504592A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
US20100179128A1 (en) Xanthine derivatives as selective hm74a agonists
US8268839B2 (en) Compounds
CA2718983C (en) Heterocyclic compounds as adenosine receptor antagonist
CA2584904A1 (en) Xanthine derivatives with hm74a receptor activity
US10278973B2 (en) Hydroxyl purine compounds and use thereof
EP1515972B1 (en) Amide substituted xanthine derivatives with gluconeogenesis modulating activity
CN101282977B (zh) 作为选择性hm74a激动剂的黄嘌呤衍生物
US20090209561A1 (en) Xanthine Derivatives with HM74A Receptor Activity
US11407758B2 (en) Tricyclic compounds, compositions and medicinal applications thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BEECHAM CORPORATION, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HATLEY, RICHARD JOHATHAN DANIEL;HEER, JAG PAUL;LIDDLE, JOHN;AND OTHERS;SIGNING DATES FROM 20060816 TO 20060918;REEL/FRAME:020490/0326

AS Assignment

Owner name: SMITHKLINE BEECHAM CORPORATION, PENNSYLVANIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ADDITIONAL INVENTOR PREVIOUSLY RECORDED ON REEL 020490 FRAME 0326. ASSIGNOR(S) HEREBY CONFIRMS THE IAN EDWARD DAVID SMITH INADVERTANTLY OMITTED FROM PREVIOUS RECORDATION.;ASSIGNORS:HATLEY, RICHARD JONATHAN DANIEL;HEER, JAG PAUL;LIDDLE, JOHN;AND OTHERS;SIGNING DATES FROM 20060816 TO 20060918;REEL/FRAME:020522/0028

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION